Health Economics›Light-chain (AL) amyloidosis›First-line therapy (including transplant ineligible)

First-line therapy (including transplant ineligible)

Light-chain (AL) amyloidosis · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CTD Variant #01	—	R 19 552	21d	—	—	~10	~R 86 855 indirect	—
VDC Variant #01	—	R 15 305	28d	~30.0 mo	—	~3	~R 45 914 PFS proxy · indirect	1
VMD Variant #01	—	R 7 516	42d	—	—	20	R 150 328 PFS proxy	1
Bortezomib and Dexamethasone (Vd) Variant #01	—	R 7 456	28d	~9.4 mo	~38.7 mo	~8	~R 59 651 PFS proxy · indirect	10
Doxycycline-CyBorD Variant #01	—	R 7 447	28d	—	—	~9	~R 67 022 indirect	—
Dara-CyBorD Variant #01 Partial	—	R 7 410	28d	—	—	~18	~R 44 460 indirect	—
CRd Variant #03	—	R 3 754	28d	—	—	~12	~R 45 051 indirect	—
MRD Variant #01	—	R 2 584	28d	—	—	~6	~R 15 503 indirect	—
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~41.0 mo	~113.8 mo	~24	~R 52 272 PFS proxy · indirect	5
Melphalan and Dexamethasone Variant #05	—	R 433	42d	—	45.5 mo	19	R 8 232 PFS proxy	2
Colchicine monotherapy Variant #01	—	R 202	28d	—	—	~2	~R 404 indirect	—
Melphalan and Prednisone (MP) Variant #18	—	R 132	42d	—	~29.1 mo	~10	~R 1 102 PFS proxy · indirect	2
No induction Partial	—	—	—	—	~31.7 mo	—	—	5
Placebo Partial	—	—	—	~22.2 mo	—	—	—	2

14 of 14 regimens shown